Skip to content

    Jupiter Life Lin

    JLHL
    Healthcare·10 Nov 2025
    Management Summary

    Jupiter Life Line Hospitals reported a solid Q2 and H1 FY26, with operating income growing 11.7% and 14.9% year-on-year respectively. EBITDA margins remained healthy at 22.8% for Q2 and 22.5% for H1. The company is on track with its expansion plans, with the Dombivali Hospital expected to commence operations in Q1 FY27 and construction for South Pune Hospital initiated. However, a one-time provision in professional fees and anticipated initial margin dilution from new hospitals were noted.

    Highlights

    5
    • Q2 FY26 Operating Income grew 11.7% YoY to ₹374.4 crores.

    • H1 FY26 Operating Income grew 14.9% YoY to ₹727.4 crores.

    • Dombivali Hospital is nearing completion and set to begin operations on schedule in Q1 FY27.

    • ARPOB for H1 FY26 improved to ₹66,100, an increase of ~15% from ₹57,700.

    • Company maintains strong liquidity with over ₹500 crores in liquid investments against ₹325 crores debt.

    Concerns

    4
    • Q2 FY26 EBITDA growth (9.3% YoY) was lower than Operating Income growth (11.7% YoY).

    • H1 FY26 PAT growth was only 5.3% YoY, significantly lower than revenue and EBITDA growth.

    • Temporary moderation of consolidated EBITDA margin expected when new hospitals like Dombivali become operational due to initial negative EBITDA.

    • One-time provision of ₹12 crores in professional fees due to new accounting treatment for unbilled revenue.

    What Changed2

    vs Q3 FY26

    Guidance items7 → 5 (-2)Risks discussed5 → 2 (-3)
    Key financials

    Metrics

    14

    Periods

    2

    Headline

    8
    • H1 Operating Income
      ₹727.4 Cr
      YoY+14.9%
    • H1 EBITDA
      ₹163.8 Cr
      YoY+13.7%
    • H1 EBITDA Margin
      22.5%
    • H1 PAT
      ₹101.4 Cr
      YoY+5.3%
    • H1 ARPOB
      ₹66,100

    Q2

    6
    • Operating Income
      ₹374.4 Cr
      YoY+11.7%
    • EBITDA
      ₹85.4 Cr
      YoY+9.3%
    • EBITDA Margin
      22.8%
    • PAT
      ₹57.4 Cr
      YoY+11%
    • Occupancy Rate
      64.5%

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    internal resources and future internal accruals

    Debt

    Gross ₹325 crores

    Cost 7.5%

    Liquidity

    Cash ₹550 crores

    Liquid investments and deposits of over Rs. 500 crores, around Rs. 550 crores at the end of September.

    Guidance & targets

    5
    CategoryTargetPriority
    Capacity
    Dombivali Hospital start of operations
    Q1 of the next financial year
    High
    Capacity
    Occupancy rate for considering expansion
    Cross 60% of installed base
    High
    Profitability
    New hospitals EBITDA margin
    EBITDA negative in the first year, break even in the second year
    High
    Profitability
    ARPOB in Dombivali
    Slightly lower than matured hospitals
    High
    Profitability
    Occupancy rate for break-even in new hospitals
    Upwards of 40%, 45%
    Medium

    Dombivali Hospital operationalization

    Q1 FY27
    CurrentNearing completion
    TargetOperations commenced

    Why it matters

    Key growth driver, will add new bed capacity and revenue stream.

    Our Dombivali Hospital is nearing completion and is set to begin operations on schedule without any foreseeable delay.

    How to verify

    guidance_and_targets[metric='Dombivali Hospital start of operations']

    Risks & concerns

    2
    RiskSeverity

    Initial margin dilution from new hospitals

    New hospitals are expected to be EBITDA negative in the first year, leading to consolidated margin dilution.Management acknowledged

    medium

    Impact of new accounting treatment for unbilled revenue

    Rs. 19.2 crores of unbilled revenue recognized in Q2, with a Rs. 12 crore one-time provision; expected to cancel out in future quarters.Analyst acknowledged

    low

    Q&A highlights

    8

    “The Dombivali Hospital, as I said, is on track. It is forecasted to start in Q1 of the next financial year... On the CAPEX side, this year so far, we have spent about Rs. 110 odd crores of CAPEX for the new project.”

    Provides concrete timelines for a key growth project and quantifies recent capital expenditure.

    asked by Mr. Rahul Jain

    2 min read6 chapters

    Detailed Narrative

    01

    Q2 & H1 FY26 Financial Performance

    Jupiter Life Line Hospitals reported a robust financial performance for Q2 and H1 FY26. The total operating income for Q2 stood at ₹374.4 crores, marking an 11.7% year-on-year increase, with EBITDA at ₹85.4 crores, growing 9.3% YoY and maintaining a 22.8% margin. For the first half of FY26, operating income reached ₹727.4 crores, up 14.9% YoY, and EBITDA was ₹163.8 crores, a 13.7% YoY increase, with a 22.5% margin. PAT for H1 FY26 grew 5.3% YoY to ₹101.4 crores.

    02

    Expansion Plans and Project Timelines

    The company's expansion strategy is well on track. The Dombivali Hospital is nearing completion and is forecasted to commence operations in Q1 of the next financial year (FY27) without anticipated delays. Construction for the South Pune Hospital has begun in Q3 FY26, and the Mira Road Hospital is currently in the architectural drawing board phase. The company has spent approximately ₹110 crores on CAPEX for new projects in H1 FY26.

    03

    Occupancy and ARPOB Trends

    For H1 FY26, the ARPOB stood at ₹66,100, and the average occupancy rate was 62.2% on expanded bed capacity. Q2 FY26 consolidated occupancy was 64.5%. Management noted that Thane hospitals are in the mid-70s occupancy, Pune is moving towards 70%, and Indore is showing increased occupancy and revenue. The Q2 occupancy in Pune was slightly lower than usual due to a reduced infection outbreak, which is a positive sign for community health.

    04

    Accounting Changes and One-time Items

    Jupiter Life Line Hospitals has adopted a new accounting treatment for unbilled revenue, recognizing ₹19.2 crores in Q2 FY26. This change also led to a one-time📎 provision of ₹12 crores in professional fees, comprising ₹3 crores for the unbilled revenue and ₹9.3 crores for unsettled/outstanding bills. Management expects this to be a one-time📎 delta, with future quarters seeing these entries broadly cancel out.

    05

    Financial Strength and Debt Position

    The company maintains a strong financial position with a consolidated debt of ₹325 crores, significantly offset by liquid investments and deposits exceeding ₹500 crores (around ₹550 crores as of September end). The blended cost of interest on the debt is between 7% and 8%, but the effective carrying cost is approximately 1% due to the substantial liquid assets. The company anticipates funding its ongoing three projects (Dombivali, South Pune, Mira Road) primarily through internal resources and future accruals.

    06

    Strategic Outlook and Payer Mix

    The company's focus remains on expanding its presence in Western India by building high-quality hospital infrastructure. The payer mix for H1 FY26 remained stable, with insurance accounting for 55.5% of revenue, self-payers 43.2%, and government schemes 1.3%. Management is open to inorganic growth opportunities in Western India, including Gujarat and Madhya Pradesh, but currently has no live discussions.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.